1型糖尿病中心脏保护辅助药物的应用
Use of Cardioprotective Adjuncts in Type 1 Diabetes.
作者信息
Greenfield Jerry R, Frampton Ruth, Millard Kellie, Snaith Jennifer R
机构信息
Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
St. Vincent's Clinical Campus, Faculty of Medicine and Health, UNSW, Sydney, Australia.
出版信息
Diabetes Ther. 2025 Feb;16(2):145-148. doi: 10.1007/s13300-024-01687-3. Epub 2025 Jan 6.
Abstract
Type 1 diabetes is associated with excess cardiovascular risk, even after accounting for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document the metabolic abnormalities that contribute to the cardiovascular mortality gap in type 1 diabetes, and to examine whether cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in this population.
摘要
1型糖尿病与心血管风险过高有关，即便在考虑了包括血糖在内的传统心血管风险因素之后亦是如此。因此，迫切需要记录导致1型糖尿病患者心血管死亡差距的代谢异常情况，并研究2型糖尿病的心脏保护药物能否预防该人群的过早发病和死亡。
相似文献
1
Use of Cardioprotective Adjuncts in Type 1 Diabetes.1型糖尿病中心脏保护辅助药物的应用
Diabetes Ther. 2025 Feb;16(2):145-148. doi: 10.1007/s13300-024-01687-3. Epub 2025 Jan 6.
2
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
3
Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.2 型糖尿病的患者重要结局：钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的范例。
Diab Vasc Dis Res. 2024 Jul-Aug;21(4):14791641241269743. doi: 10.1177/14791641241269743.
4
Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽-1 受体激动剂及其他抗糖尿病药物新启用患者的心血管结局。
J Manag Care Spec Pharm. 2020 May;26(5):610-618. doi: 10.18553/jmcp.2020.26.5.610.
5
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白-2抑制剂联合治疗对心血管和严重肾脏事件发生率的影响：基于人群的队列研究。
BMJ. 2024 Apr 25;385:e078242. doi: 10.1136/bmj-2023-078242.
6
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes.胰高血糖素样肽-1受体激动剂、钠-葡萄糖协同转运蛋白-2抑制剂及其联合应用对糖尿病患者神经体液和线粒体激活的影响。
J Am Heart Assoc. 2025 Mar 4;14(5):e039129. doi: 10.1161/JAHA.124.039129. Epub 2025 Feb 26.
7
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
8
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖共转运蛋白-2 抑制剂及其联合应用对 2 型糖尿病患者内皮糖萼、动脉功能和心肌做功指数的影响：12 个月治疗后的结果。
J Am Heart Assoc. 2020 May 5;9(9):e015716. doi: 10.1161/JAHA.119.015716. Epub 2020 Apr 24.
9
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 受体激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者全因死亡率的关联：系统评价和荟萃分析。
JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024.
10
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂在心血管和肾脏保护方面的作用：一种超越降血糖作用的治疗方法。
Eur J Intern Med. 2022 Feb;96:26-33. doi: 10.1016/j.ejim.2021.11.008. Epub 2021 Nov 17.
引用本文的文献
1
Incretin-Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists.基于肠促胰岛素的背景胰岛素治疗辅助手段用于管理 1 型糖尿病患者的超重体重：来自意大利临床内分泌学家协会的专家意见观点
Diabetes Metab Res Rev. 2025 Sep;41(6):e70073. doi: 10.1002/dmrr.70073.
2
Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.揭示第二代肠促胰岛素类似物司美格鲁肽和替尔泊肽在1型糖尿病及成人隐匿性自身免疫性糖尿病中的治疗潜力。
J Clin Med. 2025 Feb 15;14(4):1303. doi: 10.3390/jcm14041303.
本文引用的文献
1
Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes.辅助治疗能否满足未被满足的需求？一项针对1型糖尿病成人患者的调查结果
J Patient Exp. 2024 May 25;11:23743735241257811. doi: 10.1177/23743735241257811. eCollection 2024.
2
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.替尔泊肽在超重和肥胖 1 型糖尿病成人患者中的疗效和安全性。
Diabetes Technol Ther. 2024 Jun;26(6):367-374. doi: 10.1089/dia.2024.0050. Epub 2024 Apr 18.
3
Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists.澳大利亚内分泌科医生治疗1型糖尿病的辅助治疗用药模式。
Intern Med J. 2023 Dec 29. doi: 10.1111/imj.16312.
4
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.9. 血糖治疗的药物学方法：2024 年糖尿病护理标准。
Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009.
5
Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.巴利昔替尼与新发 1 型糖尿病患者的β细胞功能。
N Engl J Med. 2023 Dec 7;389(23):2140-2150. doi: 10.1056/NEJMoa2306691.
6
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.特立帕肽和新诊断 1 型糖尿病的β细胞功能。
N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18.
7
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.SGLT2i 和 GLP-1RA 治疗 1 型糖尿病和肾血管结局：一项真实世界研究。
Diabetologia. 2023 Oct;66(10):1869-1881. doi: 10.1007/s00125-023-05975-8. Epub 2023 Jul 28.
8
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.心血管结局试验：2 型糖尿病当前管理模式的重大转变。
Cardiovasc Diabetol. 2022 Aug 4;21(1):144. doi: 10.1186/s12933-022-01575-9.
9
Predictors of arterial stiffness in adolescents and adults with type 1 diabetes: a cross-sectional study.1 型糖尿病青少年和成人动脉僵硬度的预测因素：一项横断面研究。
BMJ Open Diabetes Res Care. 2022 Jan;10(1). doi: 10.1136/bmjdrc-2021-002491.
10
Technologies in the management of type 1 diabetes.1型糖尿病的管理技术
Med J Aust. 2021 Mar;214(5):202-205.e1. doi: 10.5694/mja2.50946. Epub 2021 Feb 28.
Zotero 插件